Natixis Advisors LLC Decreases Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Key Points

• Natixis Advisors LLC reduced its holdings in Genmab A/S by 37.5%, owning 128,525 shares after selling 77,244 shares in the first quarter, with a total value of approximately $2.5 million.
• Several institutional investors have increased their stakes in Genmab A/S, including Two Sigma Investments LP, which boosted its position by 122.2% in the fourth quarter, now holding over 1.7 million shares.
• Analysts have mixed opinions on Genmab A/S, with a consensus rating of "Moderate Buy" and an average price target of $37.80, reflecting optimism despite some cautious ratings.

Natixis Advisors LLC decreased its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 37.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 128,525 shares of the company's stock after selling 77,244 shares during the quarter. Natixis Advisors LLC's holdings in Genmab A/S were worth $2,516,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of GMAB. Deep Track Capital LP purchased a new position in Genmab A/S in the 4th quarter valued at about $41,740,000. Renaissance Technologies LLC raised its holdings in shares of Genmab A/S by 7.8% during the fourth quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after acquiring an additional 139,722 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Genmab A/S by 122.2% in the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after acquiring an additional 938,455 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Genmab A/S by 168.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after acquiring an additional 1,038,400 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Genmab A/S by 18.0% in the fourth quarter. First Trust Advisors LP now owns 1,644,288 shares of the company's stock worth $34,316,000 after acquiring an additional 251,241 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Analyst Ratings Changes

GMAB has been the subject of several recent research reports. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. Truist Financial increased their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Trading Up 5.5%

Shares of GMAB stock opened at $22.69 on Friday. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $27.94. The company's 50-day moving average price is $21.73 and its 200-day moving average price is $20.87. The stock has a market cap of $14.56 billion, a price-to-earnings ratio of 12.89, a PEG ratio of 6.53 and a beta of 0.95.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The company had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. As a group, equities research analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.